Le Lézard
Classified in: Health
Subject: FDA

Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval for Bendamustine HCl Powder for IV (Treanda®)


BOCA RATON, Fla., Jan. 6, 2017 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that FDA has granted final approval of its ANDA bendamustine hydrochloride powder for IV (infusion), 25 mg/vial and 100 mg/vial, a generic version of Treanda® by Cephalon, Inc. Breckenridge, and its development and manufacturing partner Natco Pharma Limited, filed the ANDA with Paragraph IV certification on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Pursuant to settlement of the Paragraph IV litigation, Breckenridge intends to launch the ANDA on November 1, 2019, or earlier based on certain circumstances.

Treanda® is a prescription drug that is indicated to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma.  Treanda® powder for IV (infusion) generated sales of $133 million for the twelve-month period ending November, 2016 based on industry sales data.

Breckenridge's recent litigation involving Bendamustine highlights its aggressive Paragraph IV strategy.  Breckenridge currently has thirty (30) ANDAs filed and pending with FDA that contain Paragraph IV patent challenges, and intends to continue that trend in the next several years, focusing on niche and first-to-file Paragraph IV opportunities with certain barriers to entry. 

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held own label Distributor that performs pharmaceutical research and development as well as marketing and distribution in the U.S. The company was founded in 1983 and markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by wholesalers, distributors, chains, and managed care accounts, as well as retail pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: tablets, capsules, soft gel capsules, liquids, suspensions, ophthalmics, nasal sprays, powders and injectables. www.bpirx.com

Treanda® is a trademark of Cephalon, Inc. or its affiliates.

SOURCE Breckenridge Pharmaceutical, Inc.


These press releases may also interest you

at 08:17
AMIGOS FOR KIDS, a Miami nonprofit organization founded in 1991, is dedicated to preventing child abuse and neglect by valuing children, strengthening families and educating communities. ...

at 08:15
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount....

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...



News published on and distributed by: